Acute Effect of the V2 Receptor Blocker, Tolvaptan, on Dyspnea in Patients Hospitalized With Heart Failure: Results of SECRET of CHF – Marvin Konstam, Boston, MA
Commentary: Acute Effect of the V2 Receptor Blocker, Tolvaptan, on Dyspnea in Patients Hospitalized With Heart Failure: Results of SECRET of CHF - TBD
The Targeting Acute Congestion With Tolvaptan in Congestive Heart Failure Study: A Randomized, Double blind, Placebo-controlled Trial in Acute Heart Failure - Robert Mentz, Durham, NC
Commentary: The Targeting Acute Congestion With Tolvaptan in Congestive Heart Failure Study: A Randomized, Double blind, Placebo-controlled Trial in Acute Heart Failure - TBD
PRIMA II: Can NT-proBNP-guided therapy during hospital admission for acute decompensated heart failure reduce mortality and readmissions? An international, multicenter, randomized clinical trial. – Susan Stienen, Amsterdam, Netherlands
Commentary: PRIMA II: Can NT-proBNP-guided therapy during hospital admission for acute decompensated heart failure reduce mortality and readmissions? An international, multicenter, randomized clinical trial. – Ileana Pina, New York, NY
Hemodynamic Monitoring in Advanced Heart Failure: Results from the LAPTOP-HF Trial – William Abraham, Columbus, OH
Commentary : Hemodynamic Monitoring in Advanced Heart Failure: Results from the LAPTOP-HF Trial - TBD
A Randomized Controlled Trial of a Social Worker-Aided Palliative Care Intervention in High Risk Patients with Heart Failure (SWAP-HF) – Akshay Desai, Boston, MA
Commentary: A Randomized Controlled Trial of a Social Worker-Aided Palliative Care Intervention in High Risk Patients with Heart Failure (SWAP-HF) - TBD
Palliative Care in Heart Failure: Results of a Randomized, Controlled Clinical Trial – Joseph Rogers, Durham, NC
Commentary: Palliative Care in Heart Failure: Results of a Randomized, Controlled Clinical Trial - TBD

Robert J. Mentz MD

Associate Professor of Medicine; Associate Professor, Population Health Sciences, Duke University Medical Center

Appearances